Low-Dose Sorafenib Promotes Cancer Stem Cell Expansion and Accelerated Tumor Progression in Soft Tissue Sarcomas

Sylvia M. Cruz,Khurshid R. Iranpur,Sean J. Judge,Erik Ames,Ian R. Sturgill,Lauren E. Farley,Morgan A. Darrow,Jiwon Sarah Crowley,Arta M. Monjazeb,William J. Murphy,Robert J. Canter

DOI: https://doi.org/10.3390/ijms25063351

IF: 5.6

2024-03-16

International Journal of Molecular Sciences

Abstract:The cancer stem cell (CSC) hypothesis postulates that heterogeneous human cancers harbor a population of stem-like cells which are resistant to cytotoxic therapies, thus providing a reservoir of relapse following conventional therapies like chemotherapy and radiation (RT). CSCs have been observed in multiple human cancers, and their presence has been correlated with worse clinical outcomes. Here, we sought to evaluate the impact of drug dosing of the multi-tyrosine kinase inhibitor, sorafenib, on CSC and non-CSCs in soft tissue sarcoma (STS) models, hypothesizing differential effects of sorafenib based on dose and target cell population. In vitro, human cancer cell lines and primary STS from surgical specimens were exposed to escalating doses of sorafenib to determine cell viability and expression of CSC marker aldehyde dehydrogenase (ALDH). In vivo, ALDHbright CSCs were isolated, exposed to sorafenib, and xenograft growth and survival analyses were performed. We observed that sarcoma CSCs appear to paradoxically respond to the tyrosine kinase inhibitor sorafenib at low doses with increased proliferation and stem-like function of CSCs, whereas anti-viability effects dominated at higher doses. Importantly, STS patients receiving neoadjuvant sorafenib and RT on a clinical trial (NCT00864032) showed increased CSCs post therapy, and higher ALDH scores post therapy were associated with worse metastasis-free survival. These data suggest that low-dose sorafenib may promote the CSC phenotype in STS with clinically significant effects, including increased tumor growth and higher rates of metastasis formation in sarcoma patients.

biochemistry & molecular biology,chemistry, multidisciplinary

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the effect of low - dose sorafenib on cancer stem cells (CSCs) in soft tissue sarcomas (STS) and its potential clinical significance. Specifically, the researchers focused on:

1. **Effect of low - dose sorafenib on CSCs**: The researchers hypothesized that different doses of the multi - tyrosine kinase inhibitor sorafenib have different effects on CSCs and non - CSCs. They observed the cell viability and the expression of the CSC marker aldehyde dehydrogenase (ALDH) in human cancer cell lines and primary STS cells from surgical specimens after treatment with increasing doses of sorafenib through in vitro experiments.

2. **In vivo experimental verification**: The researchers further isolated ALDH - highly - expressed CSCs through in vivo experiments, treated them with sorafenib, and carried out xenograft growth and survival analysis to evaluate the effect of low - dose sorafenib on the function of CSCs and tumor growth.

3. **Association with clinical trial data**: The researchers also analyzed the clinical data of STS patients (NCT00864032) who received neoadjuvant sorafenib and radiotherapy, and explored the relationship between the changes of CSCs after treatment and clinical outcomes, especially the relationship with metastasis - free survival (MFS).

The main findings of the study are that low - dose sorafenib can promote the proliferation and stem - cell - like function of CSCs, while high - dose sorafenib mainly shows an anti - survival effect. In addition, the number of CSCs increased after treatment in STS patients who received neoadjuvant sorafenib and radiotherapy, and a higher ALDH score was associated with a poorer metastasis - free survival. These data suggest that low - dose sorafenib may accelerate tumor growth and lead to a higher metastasis rate in STS patients by promoting the CSC phenotype.